Feb 3 (Reuters) - Indian drugmaker Alembic Pharmaceuticals (ALEM.NS), opens ... draws some of the biggest names in the business and benefits a thriving tourism sector. category Wall Street ends ...

India's Zydus Life beats profit view on strong US demand February 5, 2025 Indian drugmaker Alembic Pharmaceuticals reported ... from its mainstay generic drugs business in North America.

Alembic Pharmaceuticals Ltd share price was down by -1.57% from the previous closing price of ₹894.95. Who are peers of Alembic Pharmaceuticals Ltd? The peers of Alembic Pharmaceuticals Ltd are ...

Save your favourite. The tentative approval by the US Food & Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg, Alembic Pharmaceuticals said in a regulatory filing.

Alembic Pharma’s revenue missed our estimates (-2.2%) due to weak growth in domestic and API business. EBITDA fell short of our estimates due to a miss in revenue and higher operating expenses.

API Business is still under significant pricing pressure,” Shaunak Amin, MD, Alembic Pharmaceuticals Limited, said. The India Branded Business grew 3 percent to Rs. 614 crores for the quarter.

The India business posted ₹614 crore in revenue, marking a 3 percent YoY rise, while the Ex-US segment saw a 10 percent YoY growth, reaching ₹299 crore. The steady performance across these ...